PLEASE NOTE: *This study has been imported from ClinicalTrials.gov without additional data checks.*

Trial Description

Title

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication

Trial Acronym

AMLSG 16-10

URL of the trial

[---]*

Brief Summary in Lay Language

**This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute
Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria.**

**The primary efficacy object is to evaluate the impact of midostaurin given in combination
with intensive induction, consolidation including allogeneic hematopoietic stem cell
transplantation and single agent maintenance therapy on event-free survival (EFS) in adult
patients with AML exhibiting a FLT3-ITD.**

Sample size: 142 patients

**The treatment duration of an individual patient is between 18 and 24 months. Duration of the
study for an individual patient including treatment (induction, consolidation [chemotherapy
or allogeneic SCT], maintenance and follow-up period: 48 months**

Brief Summary in Scientific Language

[---]*

Organizational Data

- DRKS-ID: **DRKS00003969**
- Date of Registration in DRKS: **2012/05/10**
- Date of Registration in Partner Registry or other Primary Registry: **2011/11/17**
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **[---]***
- (leading) Ethics Committee Nr.: **[---]***

Secondary IDs

- EudraCT-No.
  (for studies acc. to Drug Law): **2011-003168-63**
- Primary Registry-ID: **NCT01477606 (ClinicalTrials.gov)**
- Sponsor-ID: **AMLSG 16-10 (University of Ulm)**
- Other Secondary-ID: **2011-003168-63**

Health condition or Problem studied

- Free text: **Acute Myeloid Leukemia**
- ICD10: **C92.0 - Acute myeloid leukaemia**

Interventions/Observational Groups

- Arm 1: **Drug: Midostaurin**
- Arm 2: **Drug: Cytarabine**
- Arm 3: **Drug: Daunorubicin**

Characteristics

- Study Type: **Interventional**
- Study Type Non-Interventional: **[---]***
- Allocation: **Single arm study**
- Blinding: **[---]***
- Who is blinded: **[---]***
- Control: **Uncontrolled/Single arm**
- Purpose: **Treatment**
- Assignment: **Single (group)**
- Phase: **II**
-

Study Type: **Interventional**

Study Type Non-Interventional: **[---]***

Allocation: **Single arm study**

Blinding: **[---]***

Who is blinded: **[---]***

Control: **Uncontrolled/Single arm**

Purpose: **Treatment**

Assignment: **Single (group)**

Phase: **II**

Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **[---]***

Primary Outcome

- Event-free Survival; time frame: Two years; To evaluate the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD.

Secondary Outcome

- Rate of complete remission (CR); time frame: Two months
- Relapse-free survival; time frame: four years
- overall survival; time frame: four years
- Cumulative incidence of relapse; time frame: four years
- cumulative incidence of death in CR; time frame: four years
- Target (FLT3) inhibition by measuring the FLT3 plasma inhibitory activity; time frame: four years; Evaluation of target (FLT3) inhibition by continuous dosing of midostaurin
- Quality of life; time frame: 5 years; Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics initially, in first CR, after one year,3 and 5 years after initial diagnosis.
- Rate of early deaths and hypoplastic deaths (ED/HD); time frame: two months
- Death in CR; time frame: four years
- Toxicities; time frame: between 18 and 24 months; Type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 3.0), timing and relatedness of hematological and non-hematological toxicities observed during the different treatment cycles

Countries of recruitment

- AT **Austria**

- DE **Germany**

Locations of Recruitment

- **Helios Klinikum Bad Saarow, Bad Saarow**
- **Charité Universitätsmedizin Berlin, Berlin**
- **Vivantes Klinikum Neukölln, Berlin**
- **Medizinische Universitätsklinik Bochum, Bochum**
- **Marienhospital Bochum-Herne, Bochum**
- **Universitätsklinikum Bonn, Bonn**
- **Städtisches Klinikum Braunschweig gGmbH, Braunschweig**
- **Klinikum Bremen-Mitte gGmbH, Bremen**
- **Klinikum Darmstadt, Darmstadt**
- **Universitätsklinkum Düsseldorf, Düsseldorf**
- **Kliniken Essen-Süd, Essen**
- **Klinik für Onkologie, Gastroenterologie und Allg. Innere Medizin Esslingen, Esslingen**
- **Malteser Krankenhaus St. Franziskus Hospital Flensburg, Flensburg**
- **Medizinische Universitätsklinik Freiburg, Freiburg**
- **Klinik der Justus-Liebig-Universität Gießen, Gießen**
- **Wilhelm-Anton-Hospital gGmbH Goch, Goch**
- **Universitätsmedizin Göttingen, Göttingen**
- **Asklepios Klinik Altona, Hamburg**
- **Universitätsklinikum Eppendorf, Hamburg**
- **Evangelisches Krankenhaus Hamm, Hamm**
- **Medizinische Hochschule Hannover, Hannover**
- **Klinikum Region Hannover GmbH, Hannover**
- **SLK Kliniken Heilbronn GmbH, Heilbronn**
- **Universitätskliniken des Saarlandes, Homburg/Saar**
- **Städtisches Klinikum Karlsruhe, Karlsruhe**
- **Städtisches Krankenhaus Kiel GmbH, Kiel**
- **Caritas Krankenhaus Lebach, Lebach**
- **Klinikum Lippe-Lemgo, Lemgo**
- **Märkische Kliniken GmbH Lüdenscheid, Lüdenscheid**

- **Universitätsklinikum der Johannes Gutenberg-Universität Mainz, Mainz**
- **Johannes Wesling Klinikum Minden, Minden**
- **Stauferklinikum Mutlangen, Mutlangen**
- **Klinikum rechts der Isar der TU München, München**
- **Pius Hospital Oldenburg, Oldenburg**
- **Klinikum Oldenburg, Oldenburg**
- **Klinikum Passau, Passau**
- **Caritasklinik St. Theresia Saarbrücken, Saarbrücken**
- **Klinikum Stuttgart, Stuttgart**
- **Diakonie-Klinikum Stuttgart, Stuttgart**
- **Klinikum Mutterhaus der Borromäerinnen gGmbH Trier, Trier**
- **Krankenhaus der Barmherzigen Brüder Trier, Trier**
- **Medizinische Universitätsklinik Tübingen, Tübingen**
- **University Hospital of Ulm, Ulm**
- **Schwarzwald-Baar Klinikum Villingen-Schwenningen, Villingen-Schwenningen**
- **Helios Klinikum Wuppertal, Wuppertal**

Recruitment

- Planned/Actual: **[---]***
- (Anticipated or Actual) Date of First Enrollment: **2012/05/31**
- Target Sample Size: **142**
- Monocenter/Multicenter trial: **Multicenter trial**
- National/International: **International**

Inclusion Criteria

- Gender: **Both, male and female**
- Minimum Age: **18 Years**
- Maximum Age: **70 Years**

Additional Inclusion Criteria

- Patients with suspected diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification)

- Presence of FLT3-ITD assessed in the central AMLSG reference

laboratories

- Patients considered eligible for intensive chemotherapy

- WHO performance status of ≤ 2

- Age ≥ 18 years and ≤ 70 years

- No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis (≤ 7 days)

- Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)

- Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for 3 month after the last dose of chemotherapy

- Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control

- Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for 3 month after the last dose of chemotherapy)

- Signed written informed consent.

Exclusion criteria

•AML with the following recurrent genetic abnormalities (according to WHO 2008): AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA gene fusions)

- Performance status WHO >2

- Patients with ejection fraction < 50% by MUGA or ECHO scan within 14 days of day 1

- Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)

- Uncontrolled infection

- Severe neurological or psychiatric disorder interfering with ability of giving an informed consent

- Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year

- Known positive for HIV; active HBV, HCV, or Hepatitis A infection

- Bleeding disorder independent of leukemia

- No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.

- No consent for biobanking.

Addresses

■ **Primary Sponsor**

University of Ulm

Telephone: **[---]***
Fax: **[---]***
E-mail: **[---]***
URL: **[---]***

■ **Contact for Scientific Queries**

University Hospital of Ulm
Richard F Schlenk, MD

Contact for Scientific Queries

University Hospital of Ulm
Richard F Schlenk, MD

Telephone: **[---]***
Fax: **[---]***
E-mail: **[---]***
URL: **[---]***

- **Contact for Public Queries**

Sabine Kayser, MD

Telephone: **+49-731-500-45714**
Fax: **[---]***
E-mail: **sabine.kayser at uniklinik-ulm.de**
URL: **[---]***

Sources of Monetary or Material Support

- **[---]***

Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor

Telephone: **[---]***
Fax: **[---]***
E-mail: **[---]***
URL: **[---]***

Status

- Recruitment Status: **Recruiting ongoing**
- Study Closing (LPLV): **[---]***

Trial Publications, Results and other documents

The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs.
- Translation on version: 33
- Last processed date by ClinicalTrials.gov: 2013/10/30

** This entry means the parameter is not applicable or has not been set.*

**** This entry means that data is not displayed due to insufficient data privacy clearing.*